Teva Branded Pharmaceutical Products R&D LLC
Stories
-
Teva registers Phase 2b and Phase 3 trials of TEV-53408 in non-segmental vitiligo
The study plans to enroll 1020 participants and start November 16, 2026. TEV-53408 will be compared with placebo to see if it helps bring color back to the skin.